Continuation Study for Latozinemab

Summary

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Timeline

Start

2023-12-08

Primary completion

2025-09-01

Completion

2026-01-07

Outcome

Outcome not reported

Stopped: “The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's”

Drugs

Indications